Journal of the American Chemical Society · 2014 · 52 citations · 52 references
PharmacyMedicinal ChemistryOncologyAntibody EngineeringDrug DesignDrug DiscoveryAntibody DiscoveryAntibody FunctionBiologic TherapeuticsTargeted Cancer TherapyTherapeutic Antibody DevelopmentTherapeutic Monoclonal AntibodiesActive Tumor TargetingAntibody Targeting LigandsCancer Targeting LigandsPhagocytosis EvasionProstate-specific Antigen - Targeted TherapyProstate-specific Membrane Antigen TargetingTherapeutic Antibody DesignTumor Targeting Ligands
This article reports the design, synthesis, and evaluation of a novel class of molecules of intermediate size (approximately 7000 Da), which possess both the targeting and effector functions of antibodies. These compounds—called synthetic antibody mimics targeting prostate cancer (SyAM-Ps)—bind simultaneously to prostate-specific membrane antigen and Fc gamma receptor I, thus eliciting highly selective cancer cell phagocytosis. SyAMs have the potential to combine the advantages of both small-molecule and biologic therapies, and may address many drawbacks associated with available treatments for cancer and other diseases.
52
Christian W. Tornøe, Caspar Christensen, Morten Meldal · The Journal of Organic Chemistry · 2002 · 8.5K citations
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Raphael Clynes, Terri L. Towers, Leonard G. Presta et al. · Nature Medicine · 2000 · 2.7K citations
Medicine, Cancer Biology, Oncology +15